Tampa healthcare company bets big on 6 unapproved peptides after federal policy shift
Tampa-based DataMEDS AI has struck a supply deal for six experimental peptides that have never received FDA approval, moving into a controversial corner of the prescription drug…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 2 13:27 ETSource: TBBW
From the source
Read at tbbwmag.comTampa healthcare company bets big on 6 unapproved peptides after federal policy shift
Tampa-based DataMEDS AI has struck a supply deal for six experimental peptides that have never received FDA approval, moving into a controversial corner of the prescription drug market just days after federal health officials announced a policy change affecting how the substances can be compounded and dispensed. The Nasdaq-listed healthcare company announced Monday that its subsidiary, Corexa Heal
